Ftse Mib
34.600,00
-0,65%
DAX
18.726,76
-0,21%
S&P 500
5.315,35
0,14%
NASDAQ
16.809,83
0,09%
Bitcoin
69.594,56
-2,60%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lyra Therapeutics Inc (LYRA) Lyra Therapeutics Inc (LYRA) Notizie

LYRA

Lyra Therapeutics (LYRA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LYRA
DataOraFonteTitoloSimboloCompagnia
21/05/202415:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
21/05/202415:14GlobeNewswire Inc.Lyra Therapeutics Announces Cost-Cutting Measures to Preserve CapitalNASDAQ:LYRALyra Therapeutics Inc
06/05/202413:59GlobeNewswire Inc.Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
30/04/202422:04GlobeNewswire Inc.Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
26/04/202422:51GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
21/03/202421:01GlobeNewswire Inc.Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
01/03/202422:01GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
15/02/202415:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
13/02/202422:34Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LYRALyra Therapeutics Inc
01/02/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
07/11/202322:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYRALyra Therapeutics Inc
07/11/202322:01GlobeNewswire Inc.Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
07/11/202313:00GlobeNewswire Inc.Lyra Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LYRALyra Therapeutics Inc
16/10/202313:00GlobeNewswire Inc.Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal OfficerNASDAQ:LYRALyra Therapeutics Inc
12/09/202313:00GlobeNewswire Inc.Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus SurgeryNASDAQ:LYRALyra Therapeutics Inc
01/09/202322:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LYRALyra Therapeutics Inc
29/08/202313:00GlobeNewswire Inc.Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
08/08/202322:01GlobeNewswire Inc.Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
13/07/202313:30GlobeNewswire Inc.Lyra Therapeutics to Present at William Blair Virtual Biotechnology ConferenceNASDAQ:LYRALyra Therapeutics Inc
13/07/202300:36Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:LYRALyra Therapeutics Inc
10/07/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LYRALyra Therapeutics Inc
07/07/202322:44Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LYRALyra Therapeutics Inc
28/06/202322:07Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:LYRALyra Therapeutics Inc
28/06/202322:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LYRALyra Therapeutics Inc
26/06/202323:40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LYRALyra Therapeutics Inc
15/06/202322:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LYRALyra Therapeutics Inc
09/06/202322:21Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LYRALyra Therapeutics Inc
02/06/202313:30GlobeNewswire Inc.Lyra Therapeutics to Present at Jefferies Healthcare ConferenceNASDAQ:LYRALyra Therapeutics Inc
01/06/202313:29GlobeNewswire Inc.Lyra Therapeutics Announces Closing of $50.0 Million Private PlacementNASDAQ:LYRALyra Therapeutics Inc
26/05/202313:57GlobeNewswire Inc.Lyra Therapeutics Announces $50.0 Million Private PlacementNASDAQ:LYRALyra Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LYRA

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
G
Generali
BIT
SPM
Saipem
BIT
BPE
Bper Banca
BIT
STMMI
ST Microelectronics
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TIT
Telecom Italia
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
TITR
Telecom Italia
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network